M
The startup develops cytokine-antibody fusion proteins to create first-in-class immuno-oncology drugs that specifically target advanced solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by overcoming the limitations of existing treatment options.
Updated 18 months ago
Funding
Funding not disclosed
TPFunding rounds are not available yet.
Founders
Product
Features
- The startup develops cytokine-antibody fusion proteins to create first-in-class immuno-oncology drugs that specifically target advanced solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by overcoming the limitations of existing treatment options.